Elevated expression of the macrophage migration inhibitory factor (MIF) has been reported in various solid tumors including colon cancer, lung cancer, breast cancer, pancreatic cancer, melanoma, nasopharyngeal carcinoma, cervical adenocarcinoma, and prostate cancer, and correlated with poor prognosis in patients with cancer [41]. Here, MIF is linked to prostate carcinoma.